Salix and Alfa Wassermann expand rifaximin accord
05:24 EDT 10 Aug 2012 | thePharmaLetter
USA-based Salix Pharmaceuticals (Nasdaq: SLXP) and Italy's Alfa Wassermann have entered into an exclusive agreement by which Salix has licensed rights in the USA and Canada to an extended intestinal release (EIR) formulation of rifaximin for gastroin..
Original Article: Salix and Alfa Wassermann expand rifaximin accord
More From BioPortfolio on "Salix and Alfa Wassermann expand rifaximin accord"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
